8-K Announcements
6Material company update
Mar 20, 2026·SEC
Material company update
Feb 5, 2026·SEC
Material company update
Jan 12, 2026·SEC
Arrowhead Pharmaceuticals, Inc.(ARWR)Earnings, Financials & Key Ratios
ARWR•NASDAQ
$79.14
$11.08B mkt cap·Price updated May 6, 2026
AboutArrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.Show more
- Revenue$829M+23258.2%
- EBITDA$122M+121.0%
- Net Income-$2M+99.7%
- EPS (Diluted)-0.01+99.8%
- Gross Margin97.12%+122.9%
- EBITDA Margin14.74%+100.1%
- Operating Margin11.86%+100.1%
- Net Margin-0.2%+100.0%
- ROE-0.47%+99.8%
- ROIC9.32%+115.5%
- Debt/Equity0.73-83.7%
- Interest Coverage1.58+108.8%
ARWR Key Insights
Arrowhead Pharmaceuticals, Inc. (ARWR) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y profit CAGR of 54.6%
- ✓FCF machine: 18.9% free cash flow margin
- ✓Momentum leader: RS Rating 94 (top 6%)
- ✓Strong 5Y sales CAGR of 56.6%
- ✓Trading near 52-week high
✗Weaknesses
- ✗Shares diluted 11.7% in last year
- ✗Expensive at 21.0x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ARWR Price & Volume
Arrowhead Pharmaceuticals, Inc. (ARWR) stock price & volume — 10-year historical chart
Loading chart...
ARWR Growth Metrics
Arrowhead Pharmaceuticals, Inc. (ARWR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years115.61%
5 Years56.63%
3 Years50.52%
TTM43539.24%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM131.62%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM129.67%
Return on Capital
10 Years-32.16%
5 Years-31.26%
3 Years-31.94%
Last Year8.83%
ARWR Recent Earnings
Arrowhead Pharmaceuticals, Inc. (ARWR) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/12 qtrs (17%)●Beat Revenue 4/12 qtrs (40%)
Q1 2026Latest
Feb 5, 2026EPS
$0.22
Est $0.60
-63.3%
Revenue
$264M
Est $214M
+23.4%
Q4 2025
Nov 25, 2025EPS
$0.18
Est $0.11
-61.3%
Revenue
$256M
Est $175M
+46.3%
Q3 2025
Aug 7, 2025EPS
$1.26
Est $0.94
-34.0%
Revenue
$28M
Est $154M
-82.0%
Q2 2025
May 12, 2025EPS
$2.75
Est $0.06
+4683.3%
Revenue
$543M
Est $116M
+366.8%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q1 2026Latest | Feb 5, 2026 | $0.22vs $0.60-63.3% | $264Mvs $214M+23.4% |
| Q4 2025 | Nov 25, 2025 | $0.18vs $0.11-61.3% | $256Mvs $175M+46.3% |
| Q3 2025 | Aug 7, 2025 | $1.26vs $0.94-34.0% | $28Mvs $154M-82.0% |
| Q2 2025 | May 12, 2025 | $2.75vs $0.06+4683.3% | $543Mvs $116M+366.8% |
Based on last 12 quarters of dataView full earnings history →
ARWR Peer Comparison
Arrowhead Pharmaceuticals, Inc. (ARWR) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ALNY | 40.43B | 303.00 | 130.04 | 65.19% | 13.46% | 98.29% | 1.62 | |
 NTLA | 1.61B | 13.85 | -3.64 | -100% | -61.47% | 0.14 | ||
 BEAM | 3.32B | 32.33 | -39.92 | 120.01% | -57.24% | -7.31% | 0.24 | |
 SRPT | 2.42B | 23.03 | -3.23 | 15.58% | 2.98% | 4.89% | 0.91 | |
 IONS | 12.7B | 76.85 | -32.29 | 33.87% | -30.87% | -58.57% | 5.35 | |
 REGN | 74.89B | 720.78 | 17.38 | 0.99% | 29.65% | 14.32% | 0.09 | |
 MDGL | 12.38B | 539.73 | -42.00 | 432.05% | -27.32% | -50.15% | 0.59 | |
 AKRO | 4.5B | 54.65 | -14.57 | -30.58% | 0.05 |
Compare ARWR vs Peers
Arrowhead Pharmaceuticals, Inc. (ARWR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ARWR Income Statement
Arrowhead Pharmaceuticals, Inc. (ARWR) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 31.41M | 16.14M | 168.8M | 87.99M | 138.29M | 243.23M | 240.74M | 3.55M | 829.45M | 1.09B |
| Revenue Growth % | 19736.49% | -48.6% | 945.67% | -47.87% | 57.16% | 75.89% | -1.03% | -98.52% | 23258.15% | 43539.24% |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 10.42M | 12.49M | 18.59M | 23.93M | 25.08M |
| COGS % of Revenue | - | - | - | - | - | 4.28% | 5.19% | 523.66% | 2.88% | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 232.81M▲ 0% | 228.24M▼ 2.0% | -15.04M▼ 106.6% | 805.52M▲ 5454.4% | 1.07B▲ 0% |
| Gross Margin % | - | - | - | - | - | 95.72% | 94.81% | -423.66% | 97.12% | 97.7% |
| Gross Profit Growth % | - | - | - | - | - | - | -1.96% | -106.59% | 5454.43% | - |
| Operating Expenses | 63.71M | 67.38M | 103.17M | 175.21M | 279.06M | 411.32M | 433.24M | 586.04M | 707.17M | 765.33M |
| OpEx % of Revenue | 202.86% | 417.41% | 61.12% | 199.12% | 201.8% | 169.11% | 179.97% | 16503.41% | 85.26% | - |
| Selling, General & Admin | 17.46M | 19.08M | 26.54M | 51.66M | 80.08M | 122.82M | 90.93M | 96.82M | 121.92M | 141.03M |
| SG&A % of Revenue | 55.6% | 118.22% | 15.72% | 58.72% | 57.91% | 50.49% | 37.77% | 2726.56% | 14.7% | - |
| Research & Development | 46.25M | 48.3M | 76.63M | 123.54M | 198.98M | 288.5M | 342.31M | 489.22M | 585.26M | 624.3M |
| R&D % of Revenue | 147.26% | 299.19% | 45.4% | 140.4% | 143.89% | 118.61% | 142.19% | 13776.85% | 70.56% | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -37M▲ 0% | -55.94M▼ 51.2% | 61.19M▲ 209.4% | -93.16M▼ 252.2% | -149.04M▼ 60.0% | -178.51M▼ 19.8% | -205M▼ 14.8% | -601.08M▼ 193.2% | 98.35M▲ 116.4% | 300.57M▲ 0% |
| Operating Margin % | -117.79% | -346.52% | 36.25% | -105.87% | -107.77% | -73.39% | -85.16% | -16927.06% | 11.86% | 27.55% |
| Operating Income Growth % | 54.74% | -51.2% | 209.39% | -252.24% | -59.98% | -19.77% | -14.84% | -193.21% | 116.36% | - |
| EBITDA | -32.31M | -51.24M | 65.63M | -87.22M | -140.77M | -168.09M | -192.51M | -582.49M | 122.27M | 325.65M |
| EBITDA Margin % | -102.86% | -317.41% | 38.88% | -99.12% | -101.79% | -69.11% | -79.97% | -16403.41% | 14.74% | 29.85% |
| EBITDA Growth % | 58.84% | -58.6% | 228.09% | -232.89% | -61.4% | -19.41% | -14.53% | -202.58% | 120.99% | 153.7% |
| D&A (Non-Cash Add-back) | 4.69M | 4.7M | 4.44M | 5.94M | 8.27M | 10.42M | 12.49M | 18.59M | 23.93M | 25.08M |
| EBIT | -37M | -55.94M | 61.19M | -93.16M | -140.85M | -172.71M | -188.16M | -580.11M | 140.89M | 345.14M |
| Net Interest Income | 415.13K | 1.05M | 6.96M | 9.19M | 6.12M | 5.03M | -3.03M | -9.63M | -52.07M | -50.84M |
| Interest Income | 415.13K | 1.05M | 6.96M | 9.19M | 6.12M | 5.03M | 15.3M | 22.72M | 37.29M | 39.38M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 18.33M | 32.35M | 89.36M | 90.22M |
| Other Income/Expense | 2.62M | 1.49M | 6.96M | 8.61M | 8.19M | 5.8M | -1.49M | -11.38M | -46.81M | -42.24M |
| Pretax Income | -34.38M▲ 0% | -54.45M▼ 58.4% | 68.15M▲ 225.2% | -84.55M▼ 224.1% | -140.85M▼ 66.6% | -172.71M▼ 22.6% | -206.49M▼ 19.6% | -612.46M▼ 196.6% | 51.53M▲ 108.4% | 258.33M▲ 0% |
| Pretax Margin % | -109.46% | -337.3% | 40.37% | -96.09% | -101.85% | -71.01% | -85.78% | -17247.54% | 6.21% | 23.68% |
| Income Tax | 2.4K | 2.4K | 174K | 2K | 2K | 3.79M | 2.78M | -2.77M | 21.42M | 24.76M |
| Effective Tax Rate % | -0.01% | -0% | 0.26% | -0% | -0% | -2.19% | -1.35% | 0.45% | 41.56% | 9.58% |
| Net Income | -34.38M▲ 0% | -54.45M▼ 58.4% | 67.97M▲ 224.8% | -84.55M▼ 224.4% | -140.85M▼ 66.6% | -176.06M▼ 25.0% | -205.28M▼ 16.6% | -599.49M▼ 192.0% | -1.63M▲ 99.7% | 202.26M▲ 0% |
| Net Margin % | -109.46% | -337.31% | 40.27% | -96.09% | -101.85% | -72.39% | -85.27% | -16882.37% | -0.2% | 18.54% |
| Net Income Growth % | 57.93% | -58.38% | 224.84% | -224.39% | -66.58% | -25% | -16.59% | -192.04% | 99.73% | 131.62% |
| Net Income (Continuing) | -34.38M | -54.45M | 67.97M | -84.55M | -140.85M | -176.49M | -209.28M | -609.69M | 30.11M | 233.57M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | -555.19K | -555.19K | -555.19K | 0 | 0 | 19.82M | 15.82M | 5.62M | 37.36M | -5.72M |
| EPS (Diluted) | -0.47▲ 0% | -0.65▼ 38.3% | 0.69▲ 206.2% | -0.84▼ 221.7% | -1.36▼ 61.9% | -1.67▼ 22.8% | -1.92▼ 15.0% | -5.00▼ 160.4% | -0.01▲ 99.8% | 1.44▲ 0% |
| EPS Growth % | 64.93% | -38.3% | 206.15% | -221.74% | -61.9% | -22.79% | -14.97% | -160.42% | 99.76% | 129.67% |
| EPS (Basic) | -0.47 | -0.65 | 0.72 | -0.84 | -1.36 | -1.67 | -1.91 | -5.00 | -0.01 | - |
| Diluted Shares Outstanding | 73.9M | 83.64M | 98.61M | 100.72M | 103.75M | 105.43M | 106.75M | 119.78M | 133.76M | 140.71M |
| Basic Shares Outstanding | 73.15M | 83.64M | 93.86M | 100.72M | 103.75M | 105.43M | 107.31M | 119.78M | 133.76M | 140.05M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ARWR Balance Sheet
Arrowhead Pharmaceuticals, Inc. (ARWR) balance sheet — assets, liabilities & shareholders' equity
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 67.9M | 78.77M | 265.25M | 322.37M | 384.6M | 405.3M | 419.52M | 695.47M | 950.64M | 1.17B |
| Cash & Short-Term Investments | 65.61M | 76.53M | 258.7M | 315.49M | 367.79M | 376.4M | 403.63M | 680.96M | 919.37M | 916.61M |
| Cash Only | 24.84M | 30.13M | 221.8M | 143.58M | 184.43M | 108M | 110.89M | 102.69M | 226.55M | 201.64M |
| Short-Term Investments | 40.77M | 46.4M | 36.9M | 171.91M | 183.35M | 268.39M | 292.74M | 578.28M | 692.82M | 714.97M |
| Accounts Receivable | 67.8K | 327.38K | 661.36K | 845.67K | 10.26M | 1.41M | 0 | 0 | 6.82M | 218.87M |
| Days Sales Outstanding | 0.79 | 7.4 | 1.43 | 3.51 | 27.07 | 2.12 | - | - | 3 | 19.89 |
| Inventory | 867.36K | 1.27M | 3.32M | 4.25M | 4.36M | -21.61M | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 1.36M | 640.12K | -754.57K | -2.47M | -2.17M | 41.82M | 7.08M | 4.97M | 13.52M | 38.91M |
| Total Non-Current Assets | 36.12M | 32.84M | 84.6M | 200.13M | 325.55M | 286.64M | 346.03M | 444.33M | 434.66M | 429.79M |
| Property, Plant & Equipment | 15.51M | 13.94M | 23.21M | 47.02M | 66.02M | 168.59M | 335.56M | 431.29M | 426.41M | 421.94M |
| Fixed Asset Turnover | 2.02x | 1.16x | 7.27x | 1.87x | 2.09x | 1.44x | 0.72x | 0.01x | 1.95x | 2.56x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 20.46M | 18.76M | 17.06M | 15.36M | 13.66M | 11.96M | 10.26M | 8.56M | 6.86M | 6.44M |
| Long-Term Investments | 0 | 0 | 44.18M | 137.49M | 245.59M | 105.87M | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 141.92K | 141.92K | 144.15K | 265.36K | 272K | 218K | 210K | 4.48M | 1.39M | 5.46M |
| Total Assets | 104.02M▲ 0% | 111.61M▲ 7.3% | 349.85M▲ 213.5% | 522.5M▲ 49.4% | 710.15M▲ 35.9% | 691.94M▼ 2.6% | 765.55M▲ 10.6% | 1.14B▲ 48.9% | 1.39B▲ 21.5% | 1.6B▲ 0% |
| Asset Turnover | 0.30x | 0.14x | 0.48x | 0.17x | 0.19x | 0.35x | 0.31x | 0.00x | 0.60x | 0.73x |
| Asset Growth % | -18.84% | 7.29% | 213.45% | 49.35% | 35.91% | -2.56% | 10.64% | 48.89% | 21.54% | 200.75% |
| Total Current Liabilities | 18.7M | 12.36M | 97.07M | 40.68M | 146.54M | 138.85M | 105.46M | 103.17M | 195.49M | 347.43M |
| Accounts Payable | 4.08M | 2.81M | 7.65M | 6.83M | 9.46M | 2.87M | 35.87M | 11.39M | 17.67M | 32.94M |
| Days Payables Outstanding | - | - | - | - | - | 100.45 | 1.05K | 223.53 | 269.6 | 340.66 |
| Short-Term Debt | 208.51K | 223.82K | 0 | 1.09M | 2.25M | 2.78M | 10.56M | 6.34M | 40M | 40M |
| Deferred Revenue (Current) | 5.71M | 600 | 77.77M | 19.29M | 111.06M | 74.1M | 866K | 0 | 2.4M | 180.58M |
| Other Current Liabilities | 5.31M | 5.4M | 6.7M | 5.41M | 14M | 46.86M | 40.2M | 63.45M | 80.43M | 10.68M |
| Current Ratio | 3.63x | 6.37x | 2.73x | 7.92x | 2.62x | 2.92x | 3.98x | 6.74x | 4.86x | 4.86x |
| Quick Ratio | 3.58x | 6.27x | 2.70x | 7.82x | 2.59x | 3.07x | 3.98x | 6.74x | 4.86x | 4.86x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -320.77 |
| Total Non-Current Liabilities | 4.45M | 4M | 8.74M | 20.04M | 154.79M | 134.75M | 372.93M | 845.57M | 686.39M | 694.06M |
| Long-Term Debt | 2.33M | 2.1M | 0 | 0 | 0 | 0 | 268.33M | 734.54M | 214.88M | 163.11M |
| Capital Lease Obligations | 0 | 0 | 0 | 20.04M | 23.3M | 78.8M | 104.61M | 111.03M | 104.11M | 419.46M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 2.13M | 1.9M | 3.7M | 0 | 0 | 0 | 0 | 0 | 367.4M | 742.39M |
| Total Liabilities | 23.16M | 16.37M | 105.81M | 60.72M | 301.33M | 273.6M | 478.39M | 948.74M | 881.88M | 1.04B |
| Total Debt | 2.53M | 2.33M | 0 | 21.14M | 25.55M | 81.58M | 383.5M | 851.91M | 366.28M | 312.77M |
| Net Debt | -22.31M | -27.81M | -221.8M | -122.44M | -158.89M | -26.43M | 272.61M | 749.23M | 139.74M | 111.12M |
| Debt / Equity | 0.03x | 0.02x | - | 0.05x | 0.06x | 0.20x | 1.34x | 4.46x | 0.73x | 0.73x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | 3.00x | 0.96x |
| Net Debt / EBITDA | - | - | -3.38x | - | - | - | - | - | 1.14x | 1.14x |
| Interest Coverage | - | - | - | - | - | - | -10.27x | -17.93x | 1.58x | 3.83x |
| Total Equity | 80.87M▲ 0% | 95.24M▲ 17.8% | 244.04M▲ 156.2% | 461.78M▲ 89.2% | 408.82M▼ 11.5% | 418.34M▲ 2.3% | 287.16M▼ 31.4% | 191.06M▼ 33.5% | 503.42M▲ 163.5% | 562.7M▲ 0% |
| Equity Growth % | -14.9% | 17.77% | 156.23% | 89.23% | -11.47% | 2.33% | -31.36% | -33.47% | 163.48% | 1158.41% |
| Book Value per Share | 1.09 | 1.14 | 2.47 | 4.58 | 3.94 | 3.97 | 2.69 | 1.60 | 3.76 | 4.00 |
| Total Shareholders' Equity | 81.42M | 95.8M | 244.59M | 461.78M | 408.82M | 398.52M | 271.34M | 185.44M | 466.05M | 568.42M |
| Common Stock | 167.16K | 180.88K | 187.88K | 194.75K | 197K | 198K | 200K | 217K | 231K | 233K |
| Retained Earnings | -432.82M | -487.27M | -419.29M | -503.84M | -644.69M | -820.75M | -1.03B | -1.63B | -1.63B | -1.6B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -53.19M | -53.19M |
| Accumulated OCI | 33.23K | -21.56K | -391.62K | 18.43K | -69K | -136K | -3.22M | 4.75M | 6.44M | 6.7M |
| Minority Interest | -555.19K | -555.19K | -555.19K | 0 | 0 | 19.82M | 15.82M | 5.62M | 37.36M | -5.72M |
ARWR Cash Flow Statement
Arrowhead Pharmaceuticals, Inc. (ARWR) cash flow — operating, investing & free cash flow history
| Line item | Sep'17 | Sep'18 | Sep'19 | Sep'20 | Sep'21 | Sep'22 | Sep'23 | Sep'24 | Sep'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -23.94M | -47.22M | 173.03M | -95.8M | 171.31M | -136.13M | -153.89M | -462.85M | 179.55M | 179.55M |
| Operating CF Margin % | -76.22% | -292.54% | 102.51% | -108.87% | 123.88% | -55.97% | -63.93% | -13034.38% | 21.65% | - |
| Operating CF Growth % | 62.84% | -97.27% | 466.42% | -155.37% | 278.82% | -179.46% | -13.05% | -200.77% | 138.79% | 788.11% |
| Net Income | -34.38M | -54.45M | 67.97M | -84.55M | -140.85M | -176.49M | -209.28M | -609.69M | 30.11M | 202.26M |
| Depreciation & Amortization | 4.69M | 4.7M | 4.44M | 5.94M | 8.27M | 10.42M | 12.49M | 18.59M | 23.93M | 25.08M |
| Stock-Based Compensation | 7.89M | 8.45M | 12.39M | 43.38M | 76.67M | 120.89M | 78.13M | 73.97M | 63.37M | 67.53M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | -933.88K | -49.07K | 1.07M | 505K | -1.44M | 7.34M | 16.31M | 29.19M | 80.38M | 85.71M |
| Working Capital Changes | -1.21M | -5.88M | 87.16M | -61.08M | 228.66M | -98.29M | -51.55M | 25.09M | -18.23M | -72.59M |
| Change in Receivables | 7.2K | -259.58K | -334K | -184K | -9.41M | 8.85M | 1.41M | 0 | -56.97M | -266.51M |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -451K |
| Change in Payables | -3.51M | -1.27M | 4.84M | -821K | 2.63M | -6.59M | 33M | -5.54M | 6.29M | 18.48M |
| Cash from Investing | -48.64M | -7.43M | -47.75M | -240.78M | -141.68M | -5.42M | -96.16M | -420.07M | -129.29M | -229.95M |
| Capital Expenditures | -7.92M | -1.42M | -12M | -11.95M | -23.57M | -52.78M | -176.74M | -141.47M | -22.67M | -17.3M |
| CapEx % of Revenue | 25.21% | 8.8% | 7.11% | 13.58% | 17.04% | 21.7% | 73.42% | 3983.92% | 2.73% | - |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 12.06M | 59.95M | 66.38M | 257.95M | 11.3M | 65.19M | 253.05M | 870.52M | 74.01M | 38.62M |
| Debt Issued (Net) | -197.79K | -208.51K | -2.42M | 0 | 0 | 0 | 0 | 392M | -191.37M | -258.05M |
| Equity Issued (Net) | 12.42M | 56.59M | 60.52M | 250.48M | 0 | 5.19M | 3.05M | 431.65M | 270.37M | 296.67M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -166.02K | 3.58M | 8.28M | 7.47M | 11.3M | 60M | 250M | 46.87M | -5M | 0 |
| Net Change in Cash | -60.53M▲ 0% | 5.29M▲ 108.7% | 191.67M▲ 3520.1% | -78.22M▼ 140.8% | 40.85M▲ 152.2% | -76.43M▼ 287.1% | 2.89M▲ 103.8% | -8.21M▼ 384.3% | 123.86M▲ 1609.4% | 147.75M▲ 0% |
| Free Cash Flow | -31.86M▲ 0% | -48.64M▼ 52.7% | 161.03M▲ 431.0% | -107.75M▼ 166.9% | 147.75M▲ 237.1% | -188.91M▼ 227.9% | -330.63M▼ 75.0% | -604.32M▼ 82.8% | 156.89M▲ 126.0% | 322.01M▲ 0% |
| FCF Margin % | -101.43% | -301.35% | 95.4% | -122.46% | 106.84% | -77.67% | -137.34% | -17018.3% | 18.91% | 29.52% |
| FCF Growth % | 53.35% | -52.7% | 431.04% | -166.91% | 237.11% | -227.86% | -75.02% | -82.78% | 125.96% | 156.33% |
| FCF per Share | -0.43 | -0.58 | 1.63 | -1.07 | 1.42 | -1.79 | -3.10 | -5.05 | 1.17 | 1.17 |
| FCF Conversion (FCF/Net Income) | 0.70x | 0.87x | 2.55x | 1.13x | -1.22x | 0.77x | 0.75x | 0.77x | -110.09x | 1.59x |
| Interest Paid | 187.65K | 173.38K | 27K | 0 | 0 | 0 | 0 | 0 | 19K | 0 |
| Taxes Paid | 2.4K | 2.4K | 302K | 0 | 2K | 2K | 0 | 3.74M | 0 | 9.98M |
ARWR Key Ratios
Arrowhead Pharmaceuticals, Inc. (ARWR) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -39.09% | -61.84% | 40.07% | -23.96% | -32.36% | -42.57% | -58.19% | -250.72% | -0.47% | 35.64% |
| Return on Invested Capital (ROIC) | -78.22% | -66.59% | 102.37% | -38.65% | -37.94% | -41.72% | -32.31% | -60.11% | 9.32% | 9.32% |
| Gross Margin | - | - | - | - | - | 95.72% | 94.81% | -423.66% | 97.12% | 97.7% |
| Net Margin | -109.46% | -337.31% | 40.27% | -96.09% | -101.85% | -72.39% | -85.27% | -16882.37% | -0.2% | 18.54% |
| Debt / Equity | 0.03x | 0.02x | - | 0.05x | 0.06x | 0.20x | 1.34x | 4.46x | 0.73x | 0.73x |
| Interest Coverage | - | - | - | - | - | - | -10.27x | -17.93x | 1.58x | 3.83x |
| FCF Conversion | 0.70x | 0.87x | 2.55x | 1.13x | -1.22x | 0.77x | 0.75x | 0.77x | -110.09x | 1.59x |
| Revenue Growth | 19736.49% | -48.6% | 945.67% | -47.87% | 57.16% | 75.89% | -1.03% | -98.52% | 23258.15% | 43539.24% |
ARWR SEC Filings & Documents
Arrowhead Pharmaceuticals, Inc. (ARWR) SEC filings — annual & quarterly reports (10-K, 10-Q)
ARWR Frequently Asked Questions
Arrowhead Pharmaceuticals, Inc. (ARWR) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Arrowhead Pharmaceuticals, Inc. (ARWR) reported $1.09B in revenue for fiscal year 2025. This represents a 1424343% increase from $0.1M in 1997.
Arrowhead Pharmaceuticals, Inc. (ARWR) grew revenue by 23258.2% over the past year. This is strong growth.
Yes, Arrowhead Pharmaceuticals, Inc. (ARWR) is profitable, generating $202.3M in net income for fiscal year 2025 (-0.2% net margin).
Dividend & Returns
Arrowhead Pharmaceuticals, Inc. (ARWR) has a return on equity (ROE) of -0.5%. Negative ROE indicates the company is unprofitable.
Arrowhead Pharmaceuticals, Inc. (ARWR) generated $322.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More ARWR
Arrowhead Pharmaceuticals, Inc. (ARWR) financial analysis — history, returns, DCA and operating performance tools
Full ARWR Stock Analysis
Analyst verdict, bull/bear case, risk factors and peer comparison
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates